source
- AstraZeneca advances obesity pill to Phase 3 after mid-stage trials show ~11% weight lossAstraZeneca announced that its experimental oral GLP-1 drug, elecoglipron, will enter an extensive Phase 3 development program following encouraging data from two mid-stage studies in obesity and d…
- Parabilis raises record $670 million in biotech IPO, the largest for a venture-backed companyParabilis Medicines, a biotech focused on "undruggable" targets, completed an initial public offering that raised $670 million, the biggest amount ever for a venture-backed biotech. The company so…